EUVIMEDEUVIMED entdecken
MetaanalyseKohortenstudieOpen Access · CC BY 4.0

Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease‐modifying antirheumatic drugs: A multi‐centre cohort study

Xinning Tong, Chin-Yao Shen, Ha-Lim Jeon iD, Yihua Li, Ju-Young Shin iD, Shirley Cw Chan, Kai Hang Yiu iD, Nicole L Pratt, Michael Ward, Chak Sing Lau, Ian Ck Wong, Xue Li iD und 1 weitere

Journal of Internal Medicine · 2023-09 · 294 (3) · 314-325

DOI: 10.1111/joim.13681 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Internal Medicine, online erschienen am 13.06.2023. Verfasst von Xinning Tong und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to compare the cardiovascular safety of interleukin‐6 inhibitors (IL‐6i) and Janus Kinase inhibitors (JAKi) to tumour necrosis factor inhibitors (TNFi).

Methods

We conducted a retrospective cohort study using population‐based electronic databases from Hong Kong, Taiwan and Korea. We identified newly diagnosed patients with rheumatoid arthritis (RA) who received b/tsDMARDs first time. We followed patients from b/tsDMARD initiation to the earliest outcome (acute coronary heart disease, stroke, heart failure, venous thromboembolism and systemic embolism) or censoring events (death, transformation of b/tsDMARDs on different targets, discontinuation and study end). Using TNFi as reference, we applied generalized linear regression for the incidence rate ratio estimation adjusted by age, sex, disease duration and comorbidities. Random effects meta‐analysis was used for pooled analysis.

Results

We identified 8689 participants for this study. Median (interquartile range) follow‐up years were 1.45 (2.77) in Hong Kong, 1.72 (2.39) in Taiwan and 1.45 (2.46) in Korea. Compared to TNFi, the adjusted incidence rate ratios (aIRRs) (95% confidence interval [CI]) of IL‐6i in Hong Kong, Taiwan and Korea are 0.99 (0.25, 3.95), 1.06 (0.57, 1.98) and 1.05 (0.59, 1.86) and corresponding aIRR of JAKi are 1.50 (0.42, 5.41), 0.60 (0.26, 1.41), and 0.81 (0.38, 1.74), respectively. Pooled aIRRs showed no significant risk of cardiovascular events (CVEs) associated with IL‐6i (1.05 [0.70, 1.57]) nor JAKi (0.80 [0.48, 1.35]) compared to TNFi.

Conclusion

There was no difference in the risk of CVE among RA patients initiated with IL‐6i, or JAKi compared to TNFi. The finding is consistent in Hong Kong, Taiwan and Korea.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesArthritis, RheumatoidAntirheumatic AgentsHumansRetrospective StudiesRisk FactorsHeart Disease Risk FactorsMulticenter Studies as Topic

Stichwörter der Autor:innen

JAK inhibitorsbDMARDscardiovascular safety of biologicsreal-world observational studyrheumatoid arthritis

Substanzen

Antirheumatic Agents

Autor:innen und Institutionen

  • Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Department of Orthopaedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
  • School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • School of Pharmacy, Jeonbuk National University, Jeonju, South Korea.
  • School of Pharmacy, Sungkyunkwan University, Seoul, South Korea.
  • Department of Biohealth Regulatory Science, Sungkyunkwan University, Seoul, South Korea.

ORCID-Profile: Ha-Lim Jeon, Ju-Young Shin, Kai Hang Yiu, Xue Li, Edward Chia-Cheng Lai

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Tong, X., Shen, C. Y., Jeon, H. L., Li, Y., Shin, J. Y., Chan, S. C., Yiu, K. H., Pratt, N. L., Ward, M., Lau, C. S., Wong, I. C., Li, X., & Lai, E. C. (2023). Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease‐modifying antirheumatic drugs: A multi‐centre cohort study. Journal of Internal Medicine, 294(3), 314-325. https://doi.org/10.1111/joim.13681

Vancouver

Tong X, Shen CY, Jeon HL, Li Y, Shin JY, Chan SC, et al. Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease‐modifying antirheumatic drugs: A multi‐centre cohort study. Journal of Internal Medicine. 2023;294(3):314-325. doi:10.1111/joim.13681

BibTeX
@article{Tong2023,
  author = {Tong, Xinning and Shen, Chin-Yao and Jeon, Ha-Lim and Li, Yihua and Shin, Ju-Young and Chan, Shirley Cw and Yiu, Kai Hang and Pratt, Nicole L and Ward, Michael and Lau, Chak Sing and Wong, Ian Ck and Li, Xue and Lai, Edward Chia-Cheng},
  title = {Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease‐modifying antirheumatic drugs: A multi‐centre cohort study},
  journal = {Journal of Internal Medicine},
  year = {2023},
  volume = {294},
  number = {3},
  pages = {314--325},
  doi = {10.1111/joim.13681}
}
Kostenlos starten →